Filing Flows › 8-K events › PJT Partners
PJT Partners: entry into a material definitive agreement
Form 8-K filed Nov 3, 2026 · items 1.01, 2.02, 2.03
Debt and financingPJT Partners Inc. Reports Third Quarter and Record Nine Months 2026 Results
What the filing says
On November 2, 2026, PJT Partners Holdings LP, a subsidiary of PJT Partners Inc. (the “Company”), as borrower (the “Borrower”), entered into an Amended and Restated Credit Agreement (the “Amendment and Restatement”) and related documents with Bank of America, N.A., also acting as administrative agent and letters of cre
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.02: +0.2% next session across 69,115. Item 2.03: 0.0% next session across 13,268. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.
PJT Partners at a glance
PJT Partners, Q3 2026: revenue $385M (-14% year over year), operating margin 17.9%. The chart follows the revenue to costs, profit and cash.
PJT Partners: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent debt and financing
- Airsculpt Technologies Nov 6, 2026
- Starry Sea Acquisition Nov 6, 2026
- Repligen Nov 6, 2026
- Evertec Nov 6, 2026
- Clean Energy Technologies Nov 6, 2026
- Reed's Nov 6, 2026
- Protagenic Therapeutics, Inc.\new Nov 6, 2026
- CNL Strategic Residential Credit Nov 6, 2026
- Health In Tech Nov 6, 2026
- Profusa Nov 6, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.